Kepler Cheuvreux initiates Coloplast stock coverage with buy rating By Investing.com

Kepler Cheuvreux initiated Coloplast A/S with a Buy rating and a DKK482 price target, arguing the recent 34% share decline has overshot fundamentals. The firm says Coloplast's core franchise accounts for about 85% of sales, supports mid- to high-single-digit organic growth, and carries structurally high 67% margins. The note frames Kerecis weakness as overdispersed across the group and sees the stock as an attractive entry point at current levels.

Analysis

The market is pricing Coloplast as if Kerecis is a structural impairment rather than a contained reset. That creates a second-order setup where the core franchise can quietly de-risk valuation through the next few quarters even without any improvement in the weaker asset: a high-quality, recurring-revenue medtech compounder at a trough multiple tends to attract both long-only re-entry and factor-driven mean reversion once the business stops being treated as a single-issue story.

The key dynamic is that investors are likely anchoring to headline growth deceleration while underweighting mix quality. If roughly the bulk of revenue is still coming from the durable core, then incremental margin and cash-flow resilience can matter more than near-term top-line optics, especially in a rate-sensitive market where stable medtech cash flows deserve a premium. The risk is that the market keeps demanding proof for another 1-2 quarters, so the rerating may be delayed even if fundamentals remain intact.

The contrarian read is that the downside case is probably more about sentiment persistence than earnings destruction. If Kerecis stabilizes or simply stops surprising negatively, the stock can re-rate without needing a full growth reacceleration; that makes this more of a normalization trade than a turnaround trade. Competitively, any forced selling or continued de-rating could be a relative opportunity for peers with less headline drag, but the better asymmetric setup here is to own the quality franchise while the market is still discounting a broader impairment than the data support.

Key Decisions for Investors

• Long CLPBY / buy the local-line equivalent on weakness, with a 3-6 month horizon; the setup is a valuation normalization trade, not a recovery-in-Kerecis bet, so upside should come from multiple expansion before operating inflection.
• Pair trade: long CLPBY vs short a lower-quality medtech peer with more cyclical or execution-sensitive growth, to isolate the rerating of a durable core franchise from broader healthcare sentiment.
• Use call spreads rather than outright stock if liquidity allows: 6-9 month bullish call spreads provide upside to a re-rating while limiting drawdown if the market keeps the stock in a penalty box for another quarter.
• Add only after the next earnings print if management confirms stable core growth and no further Kerecis disappointment; the catalyst window is likely 1-2 reporting cycles, not days.
• If the stock re-rates toward fair value before operating commentary improves, take partial profits early; this is a mean-reversion trade with finite multiple expansion rather than a multiple-bagger thesis.